Protagen Diagnostics

Protagen is the leading specialist in the development of novel in-vitro diagnostic (IVD) tests, patient stratification tools and companion diagnostics (CDx) in the fields of immuno-oncology and autoimmune diseases. With a best-in-class IP portfolio, the company combines its extensive expertise in autoantigen and autoantibody profiling with proprietary technology platforms to detect disease-relevant biomarkers, identify novel therapeutic targets and develop new diagnostic tools.

Autoimmune Diagnostic Assays

Protagen's unique autoantibody screening technologies and biological repositories support the identification of novel, exclusive, disease-specific biomarkers for the development of new IVD assays. Focusing on a number of diseases with an unmet need, Protagen’s aim is to augment current tools to improve the diagnosis and management of diseases such as RA, SSc, and SLE. New tests will allow clinicians and researchers to better differentiate between autoimmune diseases and recognize specific disease states earlier during disease onset, while also enabling more targeted and effective treatment regimens. The Multilisa SSc program includes the first of a number of new CE-approved IVD tests, Multilisa BICD2, CENP-B and Scl-70, in the pipeline. Protagen also has a number of other test programs on the horizon including Multilisa RA and SLE.

Autoimmune Patient Stratification

The ability to stratify patients into different disease subgroups based on the individual molecular characteristics of each subtype can drive better drug development and improve the success rate of clinical trials. To this end, Protagen’s NavigAID companion diagnostic concept has been designed to better stratify patients suffering with autoimmune diseases. NavigAID SLE the first to be made available so far. The NavigAID stratification tool enables differential diagnosis, better disease activity assessment and improved response prediction. Protagen has a number of other NavigAID products in the pipeline including NavigAID SSc, RA and SjS.

News

The German National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Investigate Responsiveness to Checkpoint Inhibitors in Melanoma

The German National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG today announced a collaboration to utilize Protagen’s SeroTag® technology to identify biomarkers that predict therapy responsiveness and the detection of immune-related adverse events (irAEs) in melanoma patients treated with checkpoint inhibitors.

Protagen AG successfully joined forces with Novartis to support Clinical Development of a Novel Compound in an Autoimmune Indication

PROTAGEN AG, a leading provider of pharma development services, novel diagnostic tests and companion diagnostics in the fields of immuno-oncology and autoimmune disease, today announced the successful completion a collaboration agreement with Novartis Pharma AG. During the collaboration, Protagen utilized its proprietary SeroTag technology to discover prediction as well as patient stratification markers for a novel drug being developed by Novartis.

PROTAGEN Launches NavigAID Assay to Support Clinical Drug Development for Autoimmune Diseases

Systemic Sclerosis (SSc) Disease Stratification Assay expands the NavigAID product line across multiple potential targeted therapies and disease states

Protagen AG, a leading provider of pharma development services, companion diagnostics and novel diagnostic tests in the fields of immuno-oncology and autoimmune disease, today announced the launch of NavigAID SSc, a disease stratification assay designed to support pharmaceutical and biotechnology companies with their Systemic Sclerosis (SSc) drug development efforts.